External Validation of a Prognostic Score for Survival in Lung Carcinoids.
lung carcinoid
lymph nodes
lymphadenectomy
upstaging
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 May 2022
25 May 2022
Historique:
received:
05
04
2022
revised:
17
05
2022
accepted:
23
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Background: A prognostic score including T-dimension, age, histology and lymph node ratio was previously proposed in absence of an external validation dataset. The aim of the current study was to validate the proposed prognostic score using an independent dataset. Methods: Data of patients with lung carcinoids, who underwent surgical resection and lymphadenectomy in five institutions from 1 January 2005 to 31 December 2019, were retrospectively analyzed. Two risk groups were created based on the following data: age, histology, node ratio and pT for disease-free survival (DFS); age, sex, node ratio and pT for overall survival (OS). The previously proposed score was validated, identifying two groups of patients: a high risk (HRG) and low risk (LRG) group. Results: The final analysis was conducted on 283 patients. Regarding DFS, 230 (81.3%) patients were assigned to the LRG and 53 (18.7%) to the HRG. Considering OS, 268 (94.7%) were allocated in the LRG and 15 (5.3%) in the HRG. The 5-year DFS was 92.7% in the LRG vs. 67% in the HRG (p < 0.001) while the 5-year OS was 93.6% in the LRG vs. 86.2% in the HRG (p = 0.29) with clear curve separation. Conclusion: Our analysis confirmed the validity of the composite score for DFS in lung carcinoids. Regarding OS, statistical significance was not reached because of a low number of deaths and patients in the HRG.
Identifiants
pubmed: 35681581
pii: cancers14112601
doi: 10.3390/cancers14112601
pmc: PMC9179308
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Surg Oncol. 2022 May 6;:
pubmed: 35522364
J Thorac Oncol. 2019 Jun;14(6):993-1002
pubmed: 30771520
Eur J Cardiothorac Surg. 2006 Nov;30(5):787-92
pubmed: 16971134
Ann Oncol. 2021 Apr;32(4):439-451
pubmed: 33482246
J Thorac Oncol. 2009 May;4(5):568-77
pubmed: 19357537
J Thorac Oncol. 2008 Nov;3(11):1213-23
pubmed: 18978555
J Thorac Oncol. 2019 Feb;14(2):184-192
pubmed: 30414942
J Thorac Cardiovasc Surg. 2018 Jan;155(1):405-413
pubmed: 28986041
Ann Thorac Surg. 2018 Jan;105(1):207-213
pubmed: 29132704
Lung. 2017 Dec;195(6):789-798
pubmed: 29022070
Lung Cancer. 2019 May;131:90-94
pubmed: 31027704
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Lancet Oncol. 2013 Jun;14(7):619-26
pubmed: 23680111
Ann Thorac Surg. 2018 Oct;106(4):981-988
pubmed: 29908980
Cancers (Basel). 2018 Dec 12;10(12):
pubmed: 30545054
Lung Cancer. 2020 Jan;139:94-102
pubmed: 31759223
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Ann Thorac Surg. 2004 May;77(5):1781-5
pubmed: 15111186
J Thorac Dis. 2018 Oct;10(Suppl 29):S3528-S3532
pubmed: 30510790
Interact Cardiovasc Thorac Surg. 2020 Sep 1;31(3):315-323
pubmed: 32747930
J Thorac Oncol. 2018 Apr;13(4):568-575
pubmed: 29269009
Endocr Relat Cancer. 2017 Sep;24(9):475-483
pubmed: 28684542
Eur J Cardiothorac Surg. 2015 Sep;48(3):441-7; discussion 447
pubmed: 25564217